Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.
Sartorius sells the equipment, filters, and lab tools that drugmakers and scientists use to make medicines and run experiments.
Sartorius makes the picks and shovels of the biotech world. If you're a drug company trying to turn living cells into a medicine, or a lab trying to grow and study cells, you need a lot of specialized gear to keep those cells alive and clean — and Sartorius sells much of it. The company splits into two main parts: bioprocess solutions, which makes the single-use bags, filters, and equipment that carry a medicine through every step of manufacturing, and a lab products side that sells the balances, pipettes, and cell-analysis tools scientists use at the bench.
The bioprocess side is the big money maker, and the pitch is straightforward. Making a biologic drug means growing cells in carefully controlled conditions, then separating and purifying what they produce. Sartorius sells single-use, pre-sterilized bags and filters that replace steel tanks you'd otherwise have to clean and sterilize between batches — a change that saves drugmakers time and reduces contamination risk. Once a drugmaker builds its production line around Sartorius's bags and filters, switching suppliers means re-qualifying the whole process, which makes customers sticky. The lab side is a steadier, less glamorous business: balances, water purification systems, pipettes, and instruments for counting and analyzing cells. Competitors include big established players, but Sartorius has a strong position, especially in single-use bioprocessing, where it is one of the leading suppliers. The company spent aggressively in recent years to expand manufacturing capacity, then hit a rough patch as biotech funding dried up and customers worked through stockpiled inventory after the pandemic. Orders and sales fell in 2023 and 2024, though the company has signaled that demand is gradually recovering.
One thing worth knowing: Sartorius is family-controlled and has been around since 1870, when it started making precision instruments in Göttingen, Germany, where it's still headquartered. That family anchor matters because it lets the company invest for the long haul rather than chasing quarterly numbers. Still, this is a cyclical, capital-hungry business tied to drug-development spending — when biotech funding booms, Sartorius booms with it, and when that funding freezes, its growth stalls.
Saved answer · last researched 15 Nov 2026